Form 4: Vaxcyte COO Jim Wassil Reports Stock Transactions

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the acquisition and disposition of company stock, including the grant of stock options and sales under a pre-arranged trading plan.

Summary

• On February 29, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., acquired 20,000 shares of common stock through restricted stock units (RSUs) at a price of $0.
• On the same day, Wassil was granted stock options for 90,000 shares at an exercise price of $73.82, vesting monthly starting March 31, 2024, and expiring on February 28, 2034.
• From March 1 to March 2, 2024, Wassil sold a total of 3,000 shares of common stock at weighted-average prices ranging from $73.078 to $74.695 per share, under a Rule 10b5-1 trading plan adopted on May 23, 2023.
• Additionally, 2,178 shares were surrendered to cover tax withholding obligations upon the vesting of RSUs at a price of $71.55 on March 2, 2024.
• Following these transactions, Wassil directly owns 218,674 shares of Vaxcyte common stock and holds options for 90,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected, with no clear indication of positive or negative sentiment towards the company's future prospects. The stock sales are under a pre-arranged plan.

Positives

• The grant of 90,000 stock options to the COO could be seen as an incentive to align his interests with the long-term success of the company.

Negatives

• The sale of 3,000 shares by the COO, even under a pre-arranged trading plan, could be interpreted negatively by some investors.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create uncertainty in the market.
• The vesting schedule of the RSUs and stock options is dependent on the COO's continued service with the company.

Future Outlook

The vesting schedule of the RSUs and stock options suggests a continued commitment from the COO to the company's future performance.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by investors for signals about management's confidence in the company's prospects. Rule 10b5-1 plans are often used to avoid accusations of insider trading.

Comparison to Industry Standards

• Stock option grants are a standard form of executive compensation in the biotechnology industry, often used to incentivize performance and align management interests with shareholders.
• The vesting schedules for the RSUs and stock options are typical for executive compensation packages in similar companies.
• Sales under Rule 10b5-1 plans are a common practice among executives to diversify their holdings and manage personal finances while avoiding potential insider trading concerns; companies like Amgen, Gilead, and Regeneron all have executives who utilize similar plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on their interpretation of the insider activity.
• Employees may view the stock option grants as a positive sign of the company's commitment to its executives.

Key Dates